May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Second-Line Considerations After Immune Toxicity From Prior RCC Therapy
December 21st 2022During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.
Read More
Roundtable Discussion: McKay Covers First-Line Decision-Making for Metastatic RCC
December 20th 2022During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.
Read More
CheckMate 9ER: Real World and Health-Related Quality of Life Outcomes
December 13th 2022Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.
Watch
Tivozanib Maintains PFS Benefit VS Sorafenib in R/R Renal Cell Carcinoma
November 6th 2022Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.
Read More
Lenvatinib/Pembrolizumab Upholds Efficacy Vs Sunitinib in Frontline Advanced RCC Vs Sunitinib
November 6th 2022After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.
Read More
Need for Subsequent Therapy Limited With Lenvatinib/Pembrolizumab in Advanced RCC
November 5th 2022Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.
Read More
Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
November 5th 2022Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Read More
Doctors Debate: Should Upfront Therapy for RCC Consist of Doublets or Triplets?
November 4th 2022During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc
Read More